Hydrogen treatment for chronic graft-versus-host disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the therapeutic effects of hydrogen in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (cGVHD). The investigators will assess clinical response rates, time to treatment failure, overall survival, and toxicity associated with hydrogen treatment. The aim is to determine if hydrogen can serve as an effective and safe alternative therapy for patients who do not respond to standard steroid treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent
* Male
* not pregnant female
* patients \<65 years old
* Diagnosis of cGVHD steroid refractory (no response after Prednisone ≥1mg/kg ) or steroid-dependent cGVHD (had an initial response followed by a cGVHD flare upon steroid taper)
* Patient intolerant to steroid therapy

Exclusion Criteria:

* Patients with stable disease, not well controlled by the current treatment
* Pregnancy
* HIV positive
* Severe liver or renal impairment: serum creatinine \>2.5 mg/dl; serum bilirubin\>2.5 mg/dl (without evidence of hepatic cGVHD)
* Uncontrolled malignancies including the persistence of the underlying malignancy before the Allogeneic Transplantation and the relapse of hematopoietic malignancy
* Any other investigational agents administered within last four weeks
* Cardiac insufficiency (\>grade II, New York Heart Association classification)
* Inability to comply with medical therapy or follow-up

Where it's running

• Navy General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Liren Qian, M.D.
• Email: qlr2007@126.com
• Phone: +861066957676

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belumosudil vs Best Available Therapy for chronic graft-versus-host disease

  In people aged 12 and up with chronic graft-versus-host disease, the study tests belumosudil to see if it works better than the doctor’s choice of best available therapy after prior treatments have failed.

  Recruiting at 3 sites Phase 3 Sanofi · Amsterdam and 2 other locations · NCT07771439

• Mindfulness program to help with symptoms in chronic graft-versus-host disease

  A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07733141

• Madecassoside tablets plus standard therapy for sclered scl-cGVHD after allo-HSCT

  This study tests whether adding madecassoside tablets to standard therapy can help people with scleral chronic graft-versus-host disease after stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07606703

• Post-transplant dental cleaning to prevent chronic graft-versus-host disease

  This will try a dental cleaning about 28 days after an allogeneic stem cell transplant to see if it lowers the chance of chronic graft-versus-host disease in adult transplant recipients.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT07535008

• Adrixetinib (Q702) for adults with active chronic graft-versus-host disease.

  This trial will test whether the oral drug Adrixetinib (Q702) is safe and helps adults with moderate or severe active chronic graft-versus-host disease who have not responded to standard treatments.

  Recruiting at 8 sites Phase 1 Qurient Co., Ltd. · Barcelona and 7 other locations · NCT07138196

• How whole versus crushed belumosudil tablets behave in people with chronic GVHD

  This will test whether taking belumosudil as whole tablets or crushed tablets suspended in water changes how the drug is absorbed in adults with chronic graft-versus-host disease.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07127926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.